A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study

European Journal of Preventive Cardiology
Hisao OgawaATTEMPT-CVD investigators

Abstract

A trial of telmisartan prevention of cardiovascular disease (ATTEMPT-CVD) was performed to compare the effects of angiotensin II receptor blocker (ARB) therapy and those of non-ARB standard therapy on biomarker level changes and the incidence of cardiovascular events in hypertensive patients. In this multicenter, open-label, randomized, parallel-group, comparative study, the effects of ARB therapy and those of non-ARB standard therapy on urinary albumin creatinine ratio (UACR) and plasma brain natriuretic peptide (BNP) level changes were investigated for three years from the start of antihypertensive treatment as the primary endpoints. The incidences of cardiovascular composite events were compared between the two groups, and the relationship between the incidence of the events and biomarker changes were investigated as secondary endpoints. The study started with 615 patients in the ARB group and 613 patients in the non-ARB group. The ARB group had a significant effect on UACR and plasma BNP level changes compared with the non-ARB group. Fewer cardiovascular events occurred in the ARB group, but the difference was not statistically significant. UACR and plasma BNP levels at baseline were associated with cardiovascular events. T...Continue Reading

Associated Clinical Trials

References

Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Sep 13, 2002·Journal of the American College of Cardiology·Margaret M RedfieldJohn C Burnett
Dec 24, 2004·Diabetes Care·Jorge L GrossThemis Zelmanovitz
Feb 18, 2005·The New England Journal of Medicine·Charlotte KragelundRolf Steffensen
Nov 23, 2006·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Phivos SymeonidesDemosthenes Katritsis
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Nov 8, 2008·American Journal of Hypertension·Christian DellesRoland E Schmieder
Jan 22, 2009·Journal of Hypertension·Emmanuel A AndreadisEmmanuel J Diamantopoulos
Aug 23, 2011·European Journal of Preventive Cardiology·Martin ClodiRichard Pacher
Jun 4, 2013·Journal of the American College of Cardiology·Omair YousufMatthew J Budoff

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01075698

Software Mentioned

SAS

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.